ClinicalTrialStartPulse: all 1,000 record reports, page 3 of 5

Every ClinicalTrialStartPulse record report, 200 per page, grouped by state. Records 401 to 600: Peking Union Medical College Hospital: Phase 2 study in Nonischemic Cardiomyopathy (400 participants) to University of Edinburgh: Observational study in Lynch Syndrome (1450 participants). Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2.

NONUS

• Peking Union Medical College Hospital: Phase 2 study in Nonischemic Cardiomyopathy (400 participants)
• Peking University First Hospital: Observational study in Sleep Apnea, Obstructive, Sleep Staging (1000 participants)
• Peking University People's Hospital: Observational study in Hemophagocytic Lymphohistiocytosis (HLH) (10000 participants)
• Peking University Third Hospital: Not applicable (device, behavioral) study in Femoroacetabular Impingement Syndrome (360 participants)
• Pfizer: Observational study closed enrollment, 350 enrolled (Transthyretin Amyloid Cardiopathy)
• Pfizer: Observational study closed enrollment, 4000 enrolled (Ulcerative Colitis)
• Pfizer: Observational study in Metastatic Urothelial Carcinoma, Urothelial Cancer (5122 participants)
• Pfizer: Phase 3 study in Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (3800 participants)
• Pfizer: Phase 3 study in Obesity, Overweight (432 participants)
• Pfizer: Phase 3 study in Respiratory Syncytial Virus (RSV) (750 participants)
• Poitiers University Hospital: Not applicable (device, behavioral) study started recruiting, 642 planned (Permanent Atrial Fibrillation, Preserved Ejection Fraction)
• Pontificia Universidad Catolica de Chile: Not applicable (device, behavioral) study in Hospitalisation (1167 participants)
• Puerta de Hierro University Hospital: Not applicable (device, behavioral) study closed enrollment, 390 enrolled (Chronic Heart Failure, Heart Transplant Recipient)
• Pusan National University Hospital: Observational study in Cerebral Palsy (836 participants)
• Qianfoshan Hospital: Not applicable (device, behavioral) study in PONV (718 participants)
• Qilu Hospital of Shandong University: Phase 4 study in Coronary Microvascular Disease (496 participants)
• Qilu Pharmaceutical Co., Ltd.: Phase 3 study started recruiting, 556 planned (Extensive-stage Small Cell Lung Cancer)
• Radboud University Medical Center: Not applicable (device, behavioral) study completed, 515 enrolled (Cancer)
• Radboud University Medical Center: Not applicable (device, behavioral) study in Breast Cancer Detection, Breast Cancer (2628 participants)
• Radboud University Medical Center: Observational study completed, 915 enrolled (Overweight , Obesity, Obesity (Disorder))
• Regione del Veneto - AULSS n. 7 Pedemontana: Not applicable (device, behavioral) study in Sepsis, Septic Shock (430 participants)
• RemeGen Co., Ltd.: Phase 2 study in Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy (412 participants)
• RenJi Hospital: Not applicable (device, behavioral) study in Prostate Biopsy, Sedation Complication (1146 participants)
• Research Inc: Observational study in Complications of Injectable Permanent Synthetic Fillers (450 participants)
• Royal Marsden NHS Foundation Trust: Observational study in Prostate Cancer (9007 participants)
• RTI International: Not applicable (device, behavioral) study in HIV (Human Immunodeficiency Virus) (680 participants)
• Ruijin Hospital: Not applicable (device, behavioral) study in Coronary Artery Bypass, Radial Artery Grafts (314 participants)
• Ruijin Hospital: Observational study in ARDS (Acute Respiratory Distress Syndrome), Respiratory Failure (1200 participants)
• Ruijin Hospital: Observational study in Autoimmune Pancreatitis, Pancreatic Ductal Adenocarcinoma (PDAC) (690 participants)
• Ruijin Hospital: Observational study in COPD (Chronic Obstructive Pulmonary Disease), Artificial Intelligence (466 participants)
• Ruijin Hospital: Observational study in Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma (477 participants)
• Ruijin Hospital: Phase 4 study in Atrial Fibrillation (Persistent), Catheter Ablation (472 participants)
• Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital: Observational study completed, 351 enrolled (Cardiac Surgery, Intraoperative Hemodynamic Instability)
• Samsun University: Observational study in Burn (500 participants)
• Samsung Medical Center: Observational study in Gastric Cancer, Colorectal Cancer (118750 participants)
• San Diego State University: Not applicable (device, behavioral) study started recruiting, 1000 planned (Secondary School Entry and Completion, Education Advancement)
• Sanofi: Observational study completed, 1113 enrolled (RSV Immunization)
• Sanofi: Observational study in Atherosclerotic Cardiovascular Disease (18000 participants)
• Sanofi: Observational study in Atherosclerotic Cardiovascular Disease (180000 participants)
• Sanofi: Observational study in Atherosclerotic Cardiovascular Disease (93000 participants)
• Sanofi: Observational study in Multiple Sclerosis (3000 participants)
• Sanofi: Observational study started recruiting, 670 planned (Influenza Immunization, Healthy Volunteers)
• Sanofi: Phase 3 study completed, 1602 enrolled (Meningococcal Infection, Healthy Volunteers)
• Sanofi: Phase 3 study in Immunization, Healthy Volunteers (6000 participants)
• Satelia: Observational study in Heart Failure (32380 participants)
• ScandiBio Therapeutics AB: Phase 3 study in Gout Disease (336 participants)
• Second Affiliated Hospital, Zhejiang University, School of Medicine: Not applicable (device, behavioral) study in Atrial Fibrillation (AF) (400 participants)
• Second Affiliated Hospital, Zhejiang University, School of Medicine: Observational study in Anxiety Disorders, Depressive Disorder (2690 participants)
• Second Affiliated Hospital, Zhejiang University, School of Medicine: Observational study in Erectile Dysfunction (2800 participants)
• Second Affiliated Hospital, Zhejiang University, School of Medicine: Observational study in Octogenarian Patients With Non-metastatic Resectable Colorectal Cancer (1000 participants)
• Second Affiliated Hospital, Zhejiang University, School of Medicine: Phase 3 study in Acute Ischemic Stroke (826 participants)
• Second Affiliated Hospital, Zhejiang University, School of Medicine: Phase 3 study started recruiting, 2832 planned (HFpEF - Heart Failure With Preserved Ejection Fraction, TAVI(Transcatheter Aortic Valve Implantation))
• Second Affiliated Hospital, Zhejiang University, School of Medicine: Phase 4 study in Pneumonia, Ventilator-Associated (574 participants)
• Semmelweis University: Not applicable (device, behavioral) study in Cerebral Palsy (360 participants)
• Semmelweis University: Not applicable (device, behavioral) study in Colorectal Cancer, Colorectal Neoplasms (480 participants)
• Shandong Cancer Hospital and Institute: Phase 3 study in Newly Diagnosed Triple-negative Breast Cancer (852 participants)
• Shandong Suncadia Medicine Co., Ltd.: Phase 3 study started recruiting, 914 planned (Uncontrolled or Resistant Hypertension)
• Shandong University: Not applicable (device, behavioral) study in Colorectal Polyp, Colorectal Adenoma (740 participants)
• Shanghai 6th People's Hospital: Not applicable (device, behavioral) study started recruiting, 1000 planned (Robotic Surgery, Telemedicine)
• Shanghai Bluesail Boyuan Medical Technology Co., Ltd.: Observational study in Primary Coronary Artery Calcification (390 participants)
• Shanghai East Hospital: Not applicable (device, behavioral) study in Prostate Cancer (400 participants)
• Shanghai East Hospital: Observational study in Pulmonary Nodules, Lung Neoplasms (10000 participants)
• Shanghai First Maternal and Infant Health Hospital affiliated to Tongji University Medical School: Observational study in Pregnancy, Obesity (205636 participants)
• Shanghai Hengrui Pharmaceutical Co., Ltd.: Phase 3 study in Systemic Treatment-naïve Pancreatic Cancer (825 participants)
• Shanghai Huaota Biopharmaceutical Co., Ltd.: Phase 3 study in First-line pMMR Endometrial Cancer (333 participants)
• Shanghai Jiao Tong University Affiliated Sixth People's Hospital: Not applicable (device, behavioral) study started recruiting, 448 planned (Acute Ischemic Stroke)
• Shanghai Jiao Tong University Affiliated Sixth People's Hospital: Not applicable (device, behavioral) study started recruiting, 708 planned (Acute Ischemic Stroke)
• Shanghai Jiao Tong University School of Medicine: Phase 4 study in Hypertension (456 participants)
• Shanghai Pudong Hospital: Observational study in Diabetes Mellitus, Type 2, Diabetic Nephropathies (380 participants)
• Shanghai Pudong Hospital: Observational study in Diabetic Nephropathies MeSH:D003928, Diabetes Mellitus, Type 2 (380 participants)
• Shanghai Pulmonary Hospital, Shanghai, China: Observational study in Postoperative Sore Throat, Bronchoscopy (4400 participants)
• Shanghai Zhongshan Hospital: Observational study in Sepsis, ARDS (6000 participants)
• Shanghai Zhongshan Hospital: Observational study in Sepsis, Critical Illness (2693 participants)
• Shanghai Zhongshan Hospital: Observational study in Uterine Hemorrhage, Cardiovascular Diseases (1308 participants)
• Shangqiu Normal University: Not applicable (device, behavioral) study in Adolescents' Online Moral Development, Adolescent Online Moral Disengagement (9024 participants)
• Shanxi Bethune Hospital: Observational study in Obesity & Overweight, Diabetes Mellitus, Type 2 (25974 participants)
• Sheba Medical Center: Observational study in Agranulocytosis, Neutropenia (2020 participants)
• Shengjing Hospital: Not applicable (device, behavioral) study in Stroke, Ischemic (864 participants)
• Shengjing Hospital: Observational study in Solid Neoplasms, Non-Small Cell Lung Cancer (900 participants)
• Shenzhen Salubris Pharmaceuticals Co., Ltd.: Not applicable (device, behavioral) study in Hypertension (1500 participants)
• Sichuan Baili Pharmaceutical Co., Ltd.: Phase 3 study closed enrollment, 515 enrolled (Urothelial Carcinoma)
• Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: Phase 3 study closed enrollment, 537 enrolled (Triple Negative Breast Cancer)
• SingHealth Community Hospitals: Not applicable (device, behavioral) study in Community Hospital Patients Discharging to the Community (720 participants)
• Sir Run Run Shaw Hospital: Observational study in Sepsis (3000 participants)
• Società Italiana di Medicina Interna: Observational study in Atrial Fibrillation (AF), Major Gastrointestinal Bleeding (MGIB) (650 participants)
• Sohag University: Observational study in All Pigmented Skin Tumors (400 participants)
• Sohag University: Observational study in Geographic Mismatch, Short-Term (650 participants)
• Sohag University: Observational study in Integrated Assessment, Immune-Inflammatory (400 participants)
• Sohag University: Observational study in SLE (500 participants)
• Southeast University, China: Not applicable (device, behavioral) study in Acute Respiratory Failure (ARF), Nitric Oxide (424 participants)
• Southeast University, China: Not applicable (device, behavioral) study in Diabetes Mellitus, Type 2, Influenza (759 participants)
• Southwest Hospital, China: Phase 4 study completed, 806 enrolled (Acute Ischemic Stroke Patients)
• SPECHBACH Hervé: Not applicable (device, behavioral) study in Ankle Injuries, Ankle Sprains (312 participants)
• St. Anne's University Hospital Brno, Czech Republic: Not applicable (device, behavioral) study in Atrial Fibrillation; Paroxysmal Atrial Fibrillation; Persistent Atrial Fibrillation (325 participants)
• St. Martin De Porress Hospital: Observational study in Trauma Centers/Statistics & Numerical Data, Trauma Blunt (700 participants)
• St. Petersburg State Pavlov Medical University: Observational study in Edentulism (330 participants)
• Stanford University: Not applicable (device, behavioral) study in Mental Health Help-Seeking (2100 participants)
• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University: Not applicable (device, behavioral) study in Peripheral Venous Cannulation for Contrast-enhanced CT/MRI Examination, Peripheral Venous Access Establishment (3500 participants)
• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University: Observational study in Lung Cancer Non-small Cell, Colorectal Cancer (2000 participants)
• Sun Yat-sen University: Observational study in Chemotherapy-Induced Nausea and Vomiting (CINV), Nausea (3000 participants)
• Sunway University: Observational study in Hypertension, Vascular Disease (500 participants)
• Sunway University: Observational study in Hypertension, Vascular Disease Risk (500 participants)
• Suzhou Suncadia Biopharmaceuticals Co., Ltd.: Phase 2 study in Non-small Cell Lung Cancer (660 participants)
• Suzhou Suncadia Biopharmaceuticals Co., Ltd.: Phase 3 study in Non Small Cell Lung Cancer (436 participants)
• Suzhou Suncadia Biopharmaceuticals Co., Ltd.: Phase 3 study in Non-squamous Non-small Cell Lung Cancer (490 participants)
• Swiss Tropical & Public Health Institute: Phase 3 study completed, 315 enrolled (Trichuris Trichiura, Infection)
• Taif University: Observational study in Chronic Obstructive Pulmonary Disease (COPD) (777 participants)
• Taipei Medical University WanFang Hospital: Not applicable (device, behavioral) study in Hip Fracture Surgeries, High Risk Population of Hip Fractures (450 participants)
• Taizhou Mabtech Pharmaceutical Co.,Ltd: Phase 3 study started recruiting, 362 planned (Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M))
• Takeda: Observational study closed enrollment, 402 enrolled (Narcolepsy Type 1, Narcolepsy Type 2)
• Takeda: Observational study in Narcolepsy Type 1 (400 participants)
• Takeda: Phase 3 study in Psoriatic Arthritis (644 participants)
• Tampere University Hospital: Not applicable (device, behavioral) study in Colorectal Cancer (500 participants)
• Tampere University: Not applicable (device, behavioral) study in Bronchitis, Acute, Community-acquired Pneumonia (50000 participants)
• Tata Memorial Hospital: Not applicable (device, behavioral) study closed enrollment, 850 enrolled (Non Metastatic Operable Breast Cancer)
• Tata Memorial Hospital: Phase 3 study closed enrollment, 1600 enrolled (Operable Breast Cancer)
• Tata Memorial Hospital: Phase 3 study closed enrollment, 720 enrolled (Triple Negative Breast Cancer)
• Technical University of Dortmund: Observational study closed enrollment, 627 enrolled (Age-related Cognitive Decline)
• Teva Branded Pharmaceutical Products R&D LLC: Observational study in Schizophrenia (1085 participants)
• The Affiliated Hospital of Xuzhou Medical University: Phase 4 study in ST Elevation Myocardial Infarction (STEMI) (3300 participants)
• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School: Not applicable (device, behavioral) study in Hepatic Encephalopathy, Liver Cirrhosis (394 participants)
• The First Affiliated Hospital of Air Force Medical University: Observational study in Health Literacy (1000 participants)
• The First Affiliated Hospital of Anhui Medical University: Phase 3 study started recruiting, 616 planned (Acute Ischemic Stroke)
• The First Affiliated Hospital of Bengbu Medical University: Not applicable (device, behavioral) study in Acute Ichemic Stroke (378 participants)
• The First Affiliated Hospital of Guangzhou Medical University: Not applicable (device, behavioral) study in Kidney Stones (750 participants)
• The First Affiliated Hospital of Guangzhou Medical University: Phase 4 study in Pneumococcal Polysaccharide Vaccine, Influenza Vaccines (1278 participants)
• The First Affiliated Hospital of Shanxi Medical University: Observational study in Malnutrition (1237 participants)
• The First Affiliated Hospital with Nanjing Medical University: Observational study in Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma (2000 participants)
• The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine: Observational study in Osteoporotic Vertebral Compression Fractures (360 participants)
• The First Hospital of Jilin University: Not applicable (device, behavioral) study in Acute Thoraco-Abdominal Emergency Lesions (640 participants)
• The Fourth Affiliated Hospital of Zhejiang University School of Medicine: Not applicable (device, behavioral) study in Ventilator-induced Diaphragm Dysfunction, Ventilator Dependence (400 participants)
• The George Institute: Phase 3 study in Septic Shock (2200 participants)
• The International Livestock Research Institute (ILRI): Not applicable (device, behavioral) study in Intake of Fruit, Intake of Vegetables (1143 participants)
• The Primary Health Care in the Capital Area: Not applicable (device, behavioral) study in Cervical Cancer Screening, Cervical Cancer (2000 participants)
• The Royal Wolverhampton Hospitals NHS Trust: Observational study in Myeloma Multiple (400 participants)
• The Second Affiliated Hospital of Chongqing Medical University: Not applicable (device, behavioral) study in Postoperative Sore Throat (330 participants)
• The Second Affiliated Hospital of Chongqing Medical University: Observational study in Decompensated Cirrhosis (2235 participants)
• The Second Affiliated Hospital of Chongqing Medical University: Observational study in Portal Hypertension Related to Cirrhosis, Ascites (1490 participants)
• The Third Affiliated Hospital of Southern Medical University: Observational study in Pneumothorax, Intestinal Obstruction (500 participants)
• The University of Hong Kong: Not applicable (device, behavioral) study in Suspected Neutropenic Fever, Confirmed Neutropenic Fever (317 participants)
• The University of Queensland: Observational study in Implementation Research, Kidney Disease (1390 participants)
• The University of Texas at Arlington: Not applicable (device, behavioral) study in Alcohol, Cannabis (800 participants)
• ThIA Santé Mentale: Phase 1 study in Depression Chronic, Depression and Quality of Life (608 participants)
• Third Affiliated Hospital, Sun Yat-Sen University: Not applicable (device, behavioral) study in Acute on Chronic Liver Failure (ACLF) (840 participants)
• Tianjin Medical University Cancer Institute and Hospital: Phase 4 study in Chronic Pain, Postoperative (450 participants)
• Tokyo University: Observational study in Acute Pancreatitis, Pancreatic Fluid Collection (5000 participants)
• Tongji Hospital: Observational study in Cervical Intraepithelial Neoplasia Grade 2 (CIN2) (1000 participants)
• Tor Biering-Sørensen: Phase 4 study closed enrollment, 168460 enrolled (Cardiovascular Disease, Dementia)
• Tsinghua University: Observational study in Infant Allergy, Infant Gut Health (696 participants)
• Tung Wah College: Not applicable (device, behavioral) study in Older Adults Institutionalized in Residential Homes (400 participants)
• Turku University Hospital: Observational study in Tick Borne Encephalitis (TBE), Lyme Borreliosis (850 participants)
• Ukrainian Society of Regional Anesthesia and Pain Therapy: Observational study completed, 500 enrolled (Polytrauma, Regional Anaesthesia)
• Ukrainian Society of Regional Anesthesia and Pain Therapy: Observational study in Combat-Related Limb Injury, Nerve Block (1000 participants)
• Ulsan University Hospital: Not applicable (device, behavioral) study in Coronary Artery Disease (CAD) (1258 participants)
• Ulsan University Hospital: Not applicable (device, behavioral) study in Coronary Artery Disease (CAD) (580 participants)
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: Not applicable (device, behavioral) study in Pneumonia; Pulmonary Infection (4800 participants)
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: Not applicable (device, behavioral) study in Pulmonary Nodules, Lung Neoplasms (6000 participants)
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: Observational study in Breast Cancer, HER2-negative Breast Cancer (1372 participants)
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: Observational study in Malignant Pleural Effusions (Mpe), Lung Cancer (Diagnosis) (3000 participants)
• Unity Health Toronto: Observational study in Sepsis (400 participants)
• Universidad de los Andes, Chile: Observational study in Dental Caries; Oral Health; Malocclusion (2484 participants)
• Universitätsklinikum Hamburg-Eppendorf: Observational study in Atopic Dermatitis (5000 participants)
• University College Cork: Observational study in Cerebral Palsy (CP), Intraventricular Hemorrhage Neonatal (413 participants)
• University College Hospital Galway: Observational study in Outcomes Following Major Surgery in Older Adults (500 participants)
• University College, London: Phase 3 study started recruiting, 784 planned (Tuberculosis (TB))
• University Health Network, Toronto: Observational study in Liver Cirrhosis (1000 participants)
• University Heart Center Freiburg - Bad Krozingen: Not applicable (device, behavioral) study closed enrollment, 600 enrolled (TAVI(Transcatheter Aortic Valve Implantation))
• University Hospital Augsburg: Observational study in Acute Limb Ischemia, Anticoagulants (400 participants)
• University Hospital Hradec Kralove: Not applicable (device, behavioral) study in Postpartum Quality of Life, Peripartal Maternal Trauma (380 participants)
• University Hospital Muenster: Observational study in Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (500 participants)
• University Hospital of Ferrara: Not applicable (device, behavioral) study in Aortic Stenosis Disease, Aortic Stenosis Symptomatic (450 participants)
• University Hospital, Aachen: Observational study in Schizophrenia / Schizoaffective Disorder (3692 participants)
• University Hospital, Basel, Switzerland: Observational study in Anastomotic Leaks (4300 participants)
• University Hospital, Bordeaux: Observational study in Colorectal Neoplasms (1200 participants)
• University Hospital, Bordeaux: Observational study in Intensive Care (1000 participants)
• University Hospital, Clermont-Ferrand: Not applicable (device, behavioral) study in Self-medication for Pain, Limits on Advice From Community Pharmacists and Referral to a Primary Care Practitioner (376 participants)
• University Hospital, Clermont-Ferrand: Not applicable (device, behavioral) study in TAVI(Transcatheter Aortic Valve Implantation), Left Bundle Branch Block (700 participants)
• University Hospital, Clermont-Ferrand: Phase 3 study in Breast Cancer, Breast Surgery (1600 participants)
• University Hospital, Essen: Observational study in Aneurysmal Subarachnoid Hemorrhage (10000 participants)
• University Hospital, Essen: Observational study in Hereditary Hemorrhagic Telangiectasia (HHT), Obstructive Sleep Apnea (OSA) (1000 participants)
• University Hospital, Grenoble: Not applicable (device, behavioral) study completed, 400 enrolled (Severe Chest Trauma)
• University Hospital, Strasbourg, France: Observational study in Incisional Hernia (800 participants)
• University Hospital, Strasbourg, France: Observational study in Shoulder Impingement Syndrome, Acromial Morphology (420 participants)
• University Hospital, Strasbourg, France: Observational study in Soft Tissue Sarcoma (STS) (900 participants)
• University Hospital, Strasbourg, France: Observational study in Tetralogy of Fallot (TOF), Congenital Heart Defects (400 participants)
• University Medical Center Groningen: Phase 2 study closed enrollment, 340 enrolled (NHL, DLBCL - Diffuse Large B Cell Lymphoma)
• University Medical Center Mainz: Not applicable (device, behavioral) study started recruiting, 520 planned (Mitral Regurgitation Functional, Heart Failure With Reduced Ejection Fraction (HFrEF))
• University Medical Centre Maribor: Observational study in Acute Coronary Syndromes, Chest Pain (1000 participants)
• University of Aberdeen: Observational study in Epilepsy, Antiepileptic Drugs (500 participants)
• University of Alberta: Phase 2 study completed, 713 enrolled (Low Back Pain)
• University of Bari: Observational study in Diabete Type 1 (600 participants)
• University of British Columbia: Not applicable (device, behavioral) study in Bipolar Disorder (BD), Quality of Life (QOL) (504 participants)
• University of Calgary: Not applicable (device, behavioral) study in Delirium, Intensive Care Unit Delirium (1344 participants)
• University of Calgary: Phase 3 study in Stroke, Acute Ischemic, Medium Vessel Occlusion (800 participants)
• University of California, San Francisco: Not applicable (device, behavioral) study started recruiting, 560 planned (HIV/AIDS, HIV/AIDS Prevention)
• University of Campania Luigi Vanvitelli: Observational study in Postpartum Hemorrhage, Waterbirth (600 participants)
• University of Chile: Observational study in Knee Osteoarthristis, Hip Osteoarthritis (350 participants)
• University of Colorado, Denver: Phase 4 study in Child Obesity (416 participants)
• University of Eastern Finland: Not applicable (device, behavioral) study in General Mental Health and Well-Being, Mental Disorders (1700 participants)
• University of Edinburgh: Observational study in Lynch Syndrome (1450 participants)

Browse ClinicalTrialStartPulse by category and location · Search and filter ClinicalTrialStartPulse